Myocarditis - Pipeline Review, H2 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Myocarditis - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

  • Oct 01, 2019: Cardiol Therapeutics announces completion of manufacturing scale-up for commercialization of CardiolRx 100
  • Jun 20, 2019: Cardiol Therapeutics announces plans for orphan drug program in acute myocarditis with CardiolRx CBD Formulation
  • Nov 22, 2018: LAB282: two years of drug discovery impact
  • Dec 11, 2017: Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact
  • Nov 10, 2016: Evotec and Oxford create novel Partnership called 'LAB282'

Companies Mentioned

  • Apitope International N.V.
  • Cardiol Therapeutics Inc.
  • CEL-SCI Corp.
  • Evotec SE
  • Swedish Orphan Biovitrum AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ss3lw7

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900